MM-120：新興薬剤の考察と市場予測（2032年）

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）の全般性不安障害（GAD）に対するMM-120市場について調査分析し、作用機序、用法と用量、研究開発についての考察や、市場予測などの情報を提供しています。

目次

第1章 レポートのイントロダクション

第2章 全般性不安障害におけるMM-120の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 治験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（後期の新しい治療法）

第4章 MM-120市場の評価

• 全般性不安障害におけるMM-120市場の展望
• 主要7市場分析
  • 主要7市場における全般性不安障害に対するMM-120の市場規模
• 市場分析：国別
  • 米国の全般性不安障害に対するMM-120の市場規模
  • ドイツの全般性不安障害に対するMM-120の市場規模
  • 英国の全般性不安障害に対するMM-120の市場規模

第5章 SWOT分析

第6章 アナリストの見解

第7章 付録

第8章 DelveInsightのサービス内容

第9章 免責事項

第10章 DelveInsightについて

第11章 レポート購入オプション

List of Tables

• Table 1: MM-120, Clinical Trial Description, 2023
• Table 2: MM-120, General Description
• Table 3: Competitive Landscape (Emerging Therapies)
• Table 4: MM-120 Market Size in the 7MM, in USD million (2019-2032)
• Table 5: MM-120 Market Size in the US, in USD million (2019-2032)
• Table 6: MM-120 Market Size in Germany, in USD million (2019-2032)
• Table 7: MM-120 Market Size in France, in USD million (2019-2032)
• Table 8: MM-120 Market Size in Italy, in USD million (2019-2032)
• Table 9: MM-120 Market Size in Spain, in USD million (2019-2032)
• Table 10: MM-120 Market Size in the UK, in USD million (2019-2032)
• Table 11: MM-120 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: MM-120 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: MM-120 Market Size in the United States, USD million (2019-2032)
• Figure 3: MM-120 Market Size in Germany, USD million (2019-2032)
• Figure 4: MM-120 Market Size in France, USD million (2019-2032)
• Figure 5: MM-120 Market Size in Italy, USD million (2019-2032)
• Figure 6: MM-120 Market Size in Spain, USD million (2019-2032)
• Figure 7: MM-120 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: MM-120 Market Size in Japan, USD million (2019-2032)

"MM-120 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MM-120 for Generalized Anxiety Disorder (GAD) in the seven major markets. A detailed picture of the MM-120 for Generalized Anxiety Disorder in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the MM-120 for Generalized Anxiety Disorder. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MM-120 market forecast, analysis for Generalized Anxiety Disorder in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Generalized Anxiety Disorder.

Drug Summary:

MM-120 is MindMed's proprietary drug candidate, which is a pharmacologically optimized form of lysergic acid diethylamide (LSD; it has been investigated for its applications in the treatment of anxiety associated with terminal cancer, alcoholism, opioid use disorder, and depression, among other conditions). The drug is a psychedelic drug which is being developed for GAD and other brain-based disorders and can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages, MM-120 manifests primarily in visual as well as auditory hallucinations.

In August 2022, the company initiated patient dosing in the Phase IIb dose-optimization study of MM-120 for the treatment of GAD. Patient enrollment is currently ongoing, and topline results are expected in late 2023.

The Company continues to prioritize and focus its current development efforts and resources on MM-120 in psychiatric indications. MindMed currently owns and retains all clinical data and manufacturing rights for MM-120 and is aggressively protecting and expanding its intellectual property portfolio.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the MM-120 description, mechanism of action, dosage and administration, research and development activities in Generalized Anxiety Disorder.
• Elaborated details on MM-120 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MM-120 research and development activity in Generalized Anxiety Disorder in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MM-120.
• The report contains forecasted sales of MM-120 for Generalized Anxiety Disorder till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Generalized Anxiety Disorder.
• The report also features the SWOT analysis with analyst views for MM-120 in Generalized Anxiety Disorder.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MM-120 Analytical Perspective by DelveInsight

• In-depth MM-120 Market Assessment

This report provides a detailed market assessment of MM-120 in Generalized Anxiety Disorder in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data of MM-120.

• MM-120 Clinical Assessment

The report provides the clinical trials information of MM-120 in Generalized Anxiety Disorder covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Generalized Anxiety Disorder is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MM-120 dominance.
• Other emerging products for Generalized Anxiety Disorder are expected to give tough market competition to MM-120 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MM-120 in Generalized Anxiety Disorder.
• Our in-depth analysis of the forecasted sales data of MM-120 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MM-120 in Generalized Anxiety Disorder.  

Key Questions

• What is the product type, route of administration and mechanism of action of MM-120?
• What is the clinical trial status of the study related to MM-120 in Generalized Anxiety Disorder and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MM-120 development?
• What are the key designations that have been granted to MM-120 for Generalized Anxiety Disorder?
• What is the forecasted market scenario of MM-120 for Generalized Anxiety Disorder?
• What are the forecasted sales of MM-120 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Generalized Anxiety Disorder and how are they giving competition to MM-120 for Generalized Anxiety Disorder?
• Which are the late-stage emerging therapies under development for the treatment of Generalized Anxiety Disorder?

Table of Contents

1. Report Introduction

2. MM-120 Overview in Generalized Anxiety Disorder

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. MM-120 Market Assessment

• 4.1. Market Outlook of MM-120 in Generalized Anxiety Disorder
• 4.2. 7MM Market Analysis
  • 4.2.1. Market size of MM-120 in the 7MM for Generalized Anxiety Disorder
• 4.3. Country-wise Market Analysis
  • 4.3.1. Market size of MM-120 in the United States for Generalized Anxiety Disorder
  • 4.3.2. Market size of MM-120 in Germany for Generalized Anxiety Disorder
  • 4.3.3. Market size of MM-120 in France for Generalized Anxiety Disorder
  • 4.3.4. Market size of MM-120 in Italy for Generalized Anxiety Disorder
  • 4.3.5. Market size of MM-120 in Spain for Generalized Anxiety Disorder
  • 4.3.6. Market size of MM-120 in the United Kingdom for Generalized Anxiety Disorder
  • 4.3.7. Market size of MM-120 in Japan for Generalized Anxiety Disorder

5. SWOT Analysis

6. Analysts' Views

7. Appendix

• 7.1. Bibliography
• 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options